These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15975967)

  • 1. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials.
    Aletaha D; Ward MM
    Ann Rheum Dis; 2006 Feb; 65(2):227-33. PubMed ID: 15975967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.
    Nair SC; Bijlsma JW; van der Werf JH; van der Veen MJ; Linn-Rasker SP; Vreugdenhil S; Lafeber FP; Welsing PM
    J Rheumatol; 2013 Sep; 40(9):1505-12. PubMed ID: 23818710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results.
    Aletaha D; Strand V; Smolen JS; Ward MM
    Ann Rheum Dis; 2008 Feb; 67(2):238-43. PubMed ID: 17644550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis.
    Combe B; Cantagrel A; Goupille P; Bozonnat MC; Sibilia J; Eliaou JF; Meyer O; Sany J; Dubois A; Daurès JP; Dougados M
    J Rheumatol; 2003 Nov; 30(11):2344-9. PubMed ID: 14677175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials.
    Smolen JS; Aletaha D; Grisar JC; Stamm TA; Sharp JT
    Ann Rheum Dis; 2010 Jun; 69(6):1058-64. PubMed ID: 19717399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.
    Dirven L; Visser K; Klarenbeek NB; Ewals JA; Han KH; Peeters AJ; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Scand J Rheumatol; 2012 Feb; 41(1):15-9. PubMed ID: 22103436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
    Scott DL; Strand V
    Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
    Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
    Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome.
    van Tuyl LH; Britsemmer K; Wells GA; Smolen JS; Zhang B; Funovits J; van Schaardenburg D; Felson D; Boers M
    Ann Rheum Dis; 2012 Jan; 71(1):33-7. PubMed ID: 21953347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis.
    Häkkinen A; Kautiainen H; Hannonen P; Ylinen J; Arkela-Kautiainen M; Sokka T
    Ann Rheum Dis; 2005 Jan; 64(1):59-63. PubMed ID: 15130901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
    Smolen JS; Breedveld FC; Schiff MH; Kalden JR; Emery P; Eberl G; van Riel PL; Tugwell P
    Rheumatology (Oxford); 2003 Feb; 42(2):244-57. PubMed ID: 12595618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
    Baumgartner SW; Fleischmann RM; Moreland LW; Schiff MH; Markenson J; Whitmore JB
    J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors.
    Manders SH; Kievit W; Braakman-Jansen AL; Brus HL; Hendriks L; Fransen J; van de Laar MA; van Riel PL
    J Rheumatol; 2014 Jul; 41(7):1263-9. PubMed ID: 24833758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.
    Gordon P; West J; Jones H; Gibson T
    J Rheumatol; 2001 Nov; 28(11):2409-15. PubMed ID: 11708411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
    Welsing PM; Fransen J; van Riel PL
    Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.